EYEN Stock Overview
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Eyenovia, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.98 |
| 52 Week High | US$3.34 |
| 52 Week Low | US$1.50 |
| Beta | 1.66 |
| 1 Month Change | 0.34% |
| 3 Month Change | 85.09% |
| 1 Year Change | 4.20% |
| 3 Year Change | 4.56% |
| 5 Year Change | -67.43% |
| Change since IPO | -69.96% |
Recent News & Updates
Recent updates
Does Eyenovia (NASDAQ:EYEN) Have A Healthy Balance Sheet?
Oct 25
Eyenovia gains as H.C. Wainwright initiates with Buy on pipeline potential
Oct 05Eyenovia names Michael Rowe as new CEO
Jul 27New Forecasts: Here's What One Analyst Thinks The Future Holds For Eyenovia, Inc. (NASDAQ:EYEN)
Apr 03Earnings Beat: Eyenovia, Inc. (NASDAQ:EYEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Mar 31Eyenovia: I Can See You Better - Now
Mar 04Eyenovia: Reassessing After The FDA Moves The Goalposts
Nov 23Eyenovia: FDA Setback Is Big Opportunity For Investors
Nov 08Eyenovia: Can You See Me Now?
Oct 21Is Eyenovia (NASDAQ:EYEN) A Risky Investment?
Sep 16Eyenovia updates on late-stage program for presbyopia therapy
Jun 15Eyenovia: Recent MicroLine Data, October MydCombi PDUFA Date Bode Well For Value Creation
Jun 02Eyenovia announces new $25M credit facility with Silicon Valley Bank
May 10Stuart Grant Just Bought A Sprinkling of Shares In Eyenovia, Inc. (NASDAQ:EYEN)
Mar 09Eyenovia, Inc. (NASDAQ:EYEN) Insiders Increased Their Holdings
Feb 02
Circling Back On Eyenovia
Jan 03Eyenovia seeks marketing approval for ocular therapy
Dec 29Dosing underway in Eyenovia's late-stage Microline study for presbyopia
Dec 16What Type Of Shareholders Own The Most Number of Eyenovia, Inc. (NASDAQ:EYEN) Shares?
Dec 11Eyenovia on go with late-stage study with pilocarpine formulation in presbyopia
Dec 03Shareholder Returns
| EYEN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.6% | 0.8% | 1.3% |
| 1Y | 4.2% | -5.9% | -14.6% |
Return vs Industry: EYEN exceeded the US Pharmaceuticals industry which returned -5.9% over the past year.
Return vs Market: EYEN exceeded the US Market which returned -14.6% over the past year.
Price Volatility
| EYEN volatility | |
|---|---|
| EYEN Average Weekly Movement | 10.7% |
| Pharmaceuticals Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EYEN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: EYEN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 44 | Michael Rowe | https://www.eyenovia.com |
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation.
Eyenovia, Inc. Fundamentals Summary
| EYEN fundamental statistics | |
|---|---|
| Market Cap | US$107.64m |
| Earnings (TTM) | -US$18.90m |
| Revenue (TTM) | US$10.00m |
10.8x
P/S Ratio-5.7x
P/E RatioIs EYEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EYEN income statement (TTM) | |
|---|---|
| Revenue | US$10.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$10.00m |
| Other Expenses | US$28.90m |
| Earnings | -US$18.90m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Mar 30, 2023
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 100.00% |
| Net Profit Margin | -189.04% |
| Debt/Equity Ratio | 35.6% |
How did EYEN perform over the long term?
See historical performance and comparison